Sort   by:  
 Page size 
TranscriptomicsNilotinib (Tasigna) in the Treatment of Early Diffuse Systemic Sclerosis: An Open-Label, Pilot Clinical Trial
To assess the safety, efficacy, and molecular change associated with treatment of patients with early, diffuse cutaneous systemic sclerosis (dcSSc) with nilotinib (Tasigna™). In this open-label pilot trial 6 adult patients with early dcSSc received nilotinib. Primary endpoints were safety and change...
ORGANISM(S): Homo sapiens 
2015-08-27 | E-GEOD-65405 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human K562 cells reveals Imatinib and Nilotinib induced molecular changes in Philadelphia chromosome-positive Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a malignant stem cell disease characterized by a reciprocal translocation between chromosome 9 and 22. The selective bcr-abl tyrosine-kinase inhibitor Imatinib has become the therapy of choice for patients with newly diagnosed CML including those previously cons...
ORGANISM(S): Homo sapiens 
2010-01-19 | E-GEOD-19567 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human lung cancer cells treated with dasatinib, imatinib, nilotinib or PD0325901
Cell Line: This experiment was designed to measure the transcriptional responses to four kinase inhibitors across a five-logarithm dose range. The A549 human lung cancer cell line was treated with dasatinib, imatinib or nilotinib (4 hours and 20 hours) or PD0325901 (4 hours). Treatments used a 12-po...
ORGANISM(S): Homo sapiens 
2008-12-31 | E-TABM-585 | biostudies-arrayexpress
TranscriptomicsDrug tolerance development of mouse Bcr/Abl pre-B ALL cells on irradiated MEFs
Although cure rates for acute lymphoblastic leukemia (ALL) have increased, development of resistance to drugs and patient relapse are common. The environment in which the leukemia cells are present during the drug treatment is known to provide significant survival benefit. Here, we have modeled this...
ORGANISM(S): Mus musculus 
2012-09-30 | E-GEOD-37286 | biostudies-arrayexpress
ProteomicsA MALDI-TOF assay identifies nilotinib as an inhibitor of inflammation
Inflammatory responses are important in cancer, particularly in the context of monocyte-rich aggressive myeloid neoplasm. We developed a label-free cellular phenotypic drug discovery assay to identify anti-inflammatory drugs in human monocytes derived from acute myeloid leukemia (AML), by quantifyin...
ORGANISM(S): Homo sapiens (Human) 
2022-09-30 | PXD025020 | Pride
Inhibitors of inflammation Nilotinib Maldi-tof Drug discovery Temperature proteome profiling 
TranscriptomicsCharaterization of genetic alterations and gene expression signatures found in BCR-ABL inhibitor-resistant KCL-22 subpopulations and single clones
KCL-22 is a chronic myeloid leukemia (CML) cell line derived from a patient in blast crisis phase and harbors the BCR-ABL translocation. The catalytic (ATP-competitive) BCR-ABL inhibitors imatinib and nilotinib have dramatically improved CML patient outcome, but the development of resistance remains...
ORGANISM(S): Homo sapiens 
2014-10-07 | E-GEOD-62121 | biostudies-arrayexpress
TranscriptomicsExpression in irradiated MEFs exposed to murine acute lymphoblastic leukemia cells
Primary pre-B acute lymphoblastic (ALL) cells do not proliferate long-term ex vivo without the presence of stromal support. We developed and use an ex vivo co-culture model, consisting of mouse leukemic pre-B Bcr/Abl-expressing ALL cells grown with mitotically inactivated mouse embryonic fibroblasts...
ORGANISM(S): Mus musculus 
2011-12-01 | E-GEOD-33329 | biostudies-arrayexpress
UnknownA propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
Not available
S-EPMC5073019 | biostudies-literature
ProteomicsIn vitro DDR1 signalling - Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. For instance, patients harbouring oncogenic mutations in RAS signalling do not respond to anti-EGFR targeted treatment. Therefore, RAS-independent therapies are needed. Interestingly nilotinib, a clinically approv...
ORGANISM(S): Homo sapiens (Human) 
2018-01-31 | PXD008582 | Pride
Signalling Metastatic colorectal cancer Ddr1 tyrosine kinase 
ProteomicsIn vivo DDR1 signalling - Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
The clinical management of metastatic colorectal cancer (mCRC) faces major challenges. For instance, patients harbouring oncogenic mutations in RAS signalling do not respond to anti-EGFR targeted treatment. Therefore, RAS-independent therapies are needed. Interestingly nilotinib, a clinically approv...
ORGANISM(S): Homo sapiens (Human) 
2018-01-31 | PXD008546 | Pride
Signalling Metastatic colorectal cancer Ddr1 tyrosine kinase 
Sort   by:  
 Page size